Digital Health Accelerators Digital Health Today Ambassadors Digital Health Today Podcast Digital Health Today-Resources Digital Health Today Ambassadors

Digital Health Today 360°

S3: #026: Kate Newhouse on How to Cross Borders and Overcome Obstacles in Telemedicine

How to Develop Telemedicine Solutions Globally and Locally
May 24, 2017
S3: #026: Kate Newhouse on How to Cross Borders and Overcome Obstacles in Telemedicine
Advertisement

On this show we’ve spoken to entrepreneurs that are serving needs in developed markets, we’ve spoken to entrepreneurs who are creating solutions for developing markets like those in sub-saharan Africa, but we’ve not spoken to startups that are doing both simultaneously. Today we’re changing that as we talk with Kate Newhouse, the CEO of Doctor Care Anywhere – a UK based company that is developing digital healthcare services to users in the UK and in Kenya. Kate studied history at the University of Oxford before starting a consulting career that focused on digital transformation and healthcare.

We dive into the telemedicine industry and the start of Doctor Care Anywhere, and discuss the strategy that’s helped their company succeed in growing a technology platform when neither of the two co-founders, nor their first employee had a technical background.

Today’s Topics:

  • Developments in the telemedicine industry
  • How they got funded
  • How they won their first customers
  • Who they won as their first customers
  • How they decided to expand into Kenya
  • How to grow a technology startup without being technical

Links and Resources Mentioned:

Kate Newhouse on LinkedIn:

Doctor Care Anywhere on Twitter: @DrCareAnywhere ‏

Kate Newhouse on Twitter: @Katefsnewhouse

Website: Doctorcareanywhere.com

Digital Health Events

Digital Health Jumpstart

Join Digital Health Today

Learn more about your ad choices. Visit megaphone.fm/adchoices

cover
Coffee Talk: How Corporations Adapt in the Face of New Challenges Innovating at the speed of COVID-19. PLUS: Meet the new companies in the 2020 cohort of Bayer G4A
X
X